Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes : A propensity score analysis from the CORONADO study
© 2021 John Wiley & Sons Ltd..
AIM: To investigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes in a large multicentric study.
MATERIALS AND METHODS: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs. non-users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW).
RESULTS: Five hundred and ninety-six participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW-adjusted models showed no significant association between the use of DPP-4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77-1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death.
CONCLUSIONS: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 23(2021), 5 vom: 15. Mai, Seite 1162-1172 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.05.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.14324 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320898741 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320898741 | ||
| 003 | DE-627 | ||
| 005 | 20231225174649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.14324 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320898741 | ||
| 035 | |a (NLM)33528920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Roussel, Ronan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes |b A propensity score analysis from the CORONADO study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a AIM: To investigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes in a large multicentric study | ||
| 520 | |a MATERIALS AND METHODS: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs. non-users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW) | ||
| 520 | |a RESULTS: Five hundred and ninety-six participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW-adjusted models showed no significant association between the use of DPP-4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77-1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death | ||
| 520 | |a CONCLUSIONS: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DPP-4 inhibitor | |
| 650 | 4 | |a observational study | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Dipeptidyl-Peptidase IV Inhibitors |2 NLM | |
| 700 | 1 | |a Darmon, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Pichelin, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Goronflot, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Abouleka, Yawa |e verfasserin |4 aut | |
| 700 | 1 | |a Ait Bachir, Leila |e verfasserin |4 aut | |
| 700 | 1 | |a Allix, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Ancelle, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Barraud, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Bordier, Lyse |e verfasserin |4 aut | |
| 700 | 1 | |a Carlier, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Chevalier, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Coffin-Boutreux, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Cosson, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Dorange, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Dupuy, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Fontaine, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Fremy, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a Galtier, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Germain, Natacha |e verfasserin |4 aut | |
| 700 | 1 | |a Guedj, Anne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Larger, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Laugier-Robiolle, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Laviolle, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Ludwig, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Monier, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Montanier, Nathanaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Moulin, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Prevost, Gaëtan |e verfasserin |4 aut | |
| 700 | 1 | |a Reznik, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Sabbah, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Saulnier, Pierre-Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Serusclat, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Vatier, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Wargny, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjadj, Samy |e verfasserin |4 aut | |
| 700 | 1 | |a Gourdy, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Cariou, Bertrand |e verfasserin |4 aut | |
| 700 | 0 | |a CORONADO investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 23(2021), 5 vom: 15. Mai, Seite 1162-1172 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:5 |g day:15 |g month:05 |g pages:1162-1172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.14324 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 5 |b 15 |c 05 |h 1162-1172 | ||